Expression of wild-type Rp1 protein in Rp1 knock-in mice rescues the retinal degeneration phenotype

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Liu, Qin ^a   Collin, Rob W J ^b,c   Cremers, Frans P M ^b,c   den Hollander, Anneke I ^b,c   van den Born, L Ingeborgh ^d   Pierce, Eric A ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; MUTANT PROTEIN; PROTEIN RP1; UNCLASSIFIED DRUG; VISUAL PIGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; EXON; FRAMESHIFT MUTATION; GENE FREQUENCY; HAPLOINSUFFICIENCY; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MOUSE; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PHOTORECEPTOR OUTER SEGMENT; PROTEIN EXPRESSION; RETINITIS PIGMENTOSA; RP1 GENE; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ADULT; ALLELES; ANIMALS; BASE SEQUENCE; EXONS; EYE PROTEINS; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; GENETIC THERAPY; HAPLOINSUFFICIENCY; HUMANS; MICE; MICE, TRANSGENIC; PHENOTYPE; PHOTORECEPTOR CELLS; RETINAL DEGENERATION; SEQUENCE DELETION;

EID: 84865171844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043251     Document Type: Article

References (76)

1. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
2. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
3. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, et al. (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 15112-15117.
4. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, et al. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374: 1597-1605.
5. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361: 725-727.
6. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20: 999-1004.
7. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, et al. (2009) Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration. Mol Ther 643-650.
8. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
9. Herskowitz I, (1987) Functional inactivation of genes by dominant negative mutations. Nature 329: 219-222.
10. Wilson JH, Wensel TG, (2003) The nature of dominant mutations of rhodopsin and implications for gene therapy. Mol Neurobiol 28: 149-158.
11. Veitia RA, (2009) Dominant negative factors in health and disease. J Pathol 218: 409-418.
12. Hsiau TH, Diaconu C, Myers CA, Lee J, Cepko CL, et al. (2007) The cis-regulatory logic of the mammalian photoreceptor transcriptional network. PLoS ONE 2: e643.
13. Pierce EA, (2001) Pathways to photoreceptor cell death in inherited retinal degenerations. Bioessays 23: 605-618.
14. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP, (2008) Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27: 391-419.
15. Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, et al. (1990) A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343: 364-366.
16. Cremers FP, Janne PA, Landers JE, Lewis RA, Nussbaum RL, (1990) Cloning of a gene that is rearranged in patients with choroideremia. Nature 347: 674-677.
17. RetNet (2012) RetNet Web site address, https://sph.uth.tmc.edu/retnet/.
18. Hartong DT, Berson EL, Dryja TP, (2006) Retinitis pigmentosa. Lancet 368: 1795-1809.
19. Daiger SP, Bowne SJ, Sullivan LS, (2007) Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 125: 151-158.
20. Xu L, Hu L, Ma K, Li J, Jonas JB, (2006) Prevalence of retinitis pigmentosa in urban and rural adult Chinese: The Beijing Eye Study. Eur J Ophthalmol 16: 865-866.
21. Pierce EA, Quinn T, Meehan T, McGee TL, Berson EL, et al. (1999) Mutations in a gene encoding a new oxygen-regulated photoreceptor protein cause dominant retinitis pigmentosa. Nat Genet 22: 248-254.
22. Sullivan LS, Heckenlively JR, Bowne SJ, Zuo J, Hide WA, et al. (1999) Mutations in a novel retina-specific gene cause autosomal dominant retinitis pigmentosa. Nat Genet 22: 255-259.
23. Guillonneau X, Piriev NI, Danciger M, Kozak CA, Cideciyan AV, et al. (1999) A nonsense mutation in a novel gene is associated with retinitis pigmentosa in a family linked to the RP1 locus. Hum Mol Genet 8: 1541-1546.
24. Bowne SJ, Daiger SP, Hims MM, Sohocki MM, Malone KA, et al. (1999) Mutations in the RP1 gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet 8: 2121-2128.
25. Payne A, Vithana E, Khaliq S, Hameed A, Deller J, et al. (2000) RP1 protein truncating mutations predominate at the RP1 adRP locus. Invest Ophthalmol Vis Sci 41: 4069-4073.
26. Jacobson SG, Cideciyan AV, Iannaccone A, Weleber RG, Fishman GA, et al. (2000) Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 41: 1898-1908.
27. Berson EL, Grimsby JL, Adams SM, McGee TL, Sweklo E, et al. (2001) Clinical features and mutations in patients with dominant retinitis pigmentosa-1 (RP1). Invest Ophthalmol Vis Sci 42: 2217-2224.
28. Baum L, Chan WM, Yeung KY, Lam DS, Kwok AK, et al. (2001) RP1 in Chinese: Eight novel variants and evidence that truncation of the extreme C-terminal does not cause retinitis pigmentosa. Hum Mutat 17: 436.
29. Dietrich K, Jacobi FK, Tippmann S, Schmid R, Zrenner E, et al. (2002) A novel mutation of the RP1 gene (Lys778ter) associated with autosomal dominant retinitis pigmentosa. Br J Ophthalmol 86: 328-332.
30. Kawamura M, Wada Y, Noda Y, Itabashi T, Ogawa S, et al. (2004) Novel 2336-2337delCT mutation in RP1 gene in a Japanese family with autosomal dominant retinitis pigmentosa. Am J Ophthalmol 137: 1137-1139.
31. Ziviello C, Simonelli F, Testa F, Anastasi M, Marzoli SB, et al. (2005) Molecular genetics of autosomal dominant retinitis pigmentosa (ADRP): a comprehensive study of 43 Italian families. J med Genet 42: e47.
32. Gamundi MJ, Hernan I, Martinez-Gimeno M, Maseras M, Garcia-Sandoval B, et al. (2006) Three novel and the common Arg677Ter RP1 protein truncating mutations causing autosomal dominant retinitis pigmentosa in a Spanish population. BMC Med Genet 7: 35.
33. Roberts L, Bartmann L, Ramesar R, Greenberg J, (2006) Novel variants in the hotspot region of RP1 in South African patients with retinitis pigmentosa. Mol Vis 12: 177-183.
34. Singh HP, Jalali S, Narayanan R, Kannabiran C, (2009) Genetic analysis of Indian families with autosomal recessive retinitis pigmentosa by homozygosity screening. Invest Ophthalmol Vis Sci 50: 4065-4071.
35. Liu Q, Zhou J, Daiger SP, Farber DB, Heckenlively JR, et al. (2002) Identification and Subcellular Localization of the RP1 Protein in Human and Mouse Photoreceptors. Invest Ophthalmol Vis Sci 43: 22-32.
36. Gao J, Cheon K, Nusinowitz S, Liu Q, Bei D, et al. (2002) Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rp1) gene. Proc Natl Acad Sci U S A 99: 5698-5703.
37. Liu Q, Lyubarsky A, Skalet JH, Pugh EN Jr, Pierce EA, (2003) RP1 Is Required for the Correct Stacking of Outer Segment Discs. Invest Ophthalmol Vis Sci 44: 4171-4183.
38. Liu Q, Zuo J, Pierce EA, (2004) The retinitis pigmentosa 1 protein is a photoreceptor microtubule-associated protein. J Neurosci 24: 6427-6436.
39. Khaliq S, Abid A, Ismail M, Hameed A, Mohyuddin A, et al. (2005) Novel association of RP1 gene mutations with autosomal recessive retinitis pigmentosa. J med Genet 42: 436-438.
40. Riazuddin SA, Zulfiqar F, Zhang Q, Sergeev YV, Qazi ZA, et al. (2005) Autosomal recessive retinitis pigmentosa is associated with mutations in RP1 in three consanguineous Pakistani families. Invest Ophthalmol Vis Sci 46: 2264-2270.
41. Chen LJ, Lai TY, Tam PO, Chiang SW, Zhang X, et al. (2010) Compound heterozygosity of two novel truncation mutations in RP1 causing autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 51: 2236-2242.
42. Collin RWJ, van den Born LI, Klevering BJ, de Castro-Miro M, Littink KW, et al. (2011) High-resolution homozygosity mapping is a powerful tool to detect novel mutations causative for autosomal recessive RP in the Dutch population. Invest Ophthalmol Vis Sci 52: 2227-2239.
43. Chang YF, Imam JS, Wilkinson MF, (2007) The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 76: 51-74.
44. Copeland NG, Jenkins NA, Court DL, (2001) Recombineering: a powerful new tool for mouse functional genomics. Nat Rev Genet 2: 769-779.
45. Zhang P, Li MZ, Elledge SJ, (2002) Towards genetic genome projects: genomic library screening and gene-targeting vector construction in a single step. Nat Genet 30: 31-39.
46. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25: 139-140.
47. Liu Q, Saveliev A, Pierce EA, (2009) The severity of retinal degeneration in Rp1h gene-targeted mice is dependent on genetic background. Invest Ophthalmol Vis Sci 50: 1566-1574.
48. Cheeseman IM, Desai A, (2005) A combined approach for the localization and tandem affinity purification of protein complexes from metazoans. Sci STKE 2005: l1.
49. Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M, (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7: 4228-4234.
50. Nagy A, Gertsenstein M, Vintersten K, Behringer RR (2003) Manipulating the mouse embyro. Cold Spring Harbor Laboratory Press.
51. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS, (2007) Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 47: 1202-1208.
52. Gorbatyuk MS, Hauswirth WW, Lewin AS, (2008) Gene therapy for mouse models of ADRP. Adv Exp Med Biol 613: 107-112.
53. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, et al. (2007) RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 81: 127-135.
54. Chadderton N, Millington-Ward S, Palfi A, O'Reilly M, Tuohy G, et al. (2009) Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 17: 593-599.
55. Nadeau JH, (2001) Modifier genes in mice and humans. Nat Rev Genet 2: 165-174.
56. Haider NB, Ikeda A, Naggert JK, Nishina PM, (2002) Genetic modifiers of vision and hearing. Hum Mol Genet 11: 1195-1206.
57. Bateman JF, Freddi S, Nattrass G, Savarirayan R, (2003) Tissue-specific RNA surveillance? Nonsense-mediated mRNA decay causes collagen X haploinsufficiency in Schmid metaphyseal chondrodysplasia cartilage. Hum Mol Genet 12: 217-225.
58. Olsson JE, Gordon JW, Pawlyk BS, Roof DJ, Hayes A, et al. (1992) Transgenic mice with a rhodopsin mutation (Pro23His): A mouse model of autosomal dominant retinitis pigmentosa. Neuron 9: 815-830.
59. Tan E, Wang Q, Quiambao AB, Xu X, Qtaishat NM, et al. (2001) The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci 42: 589-600.
60. Michaelson D, Philips M, (2006) The use of GFP to localize Rho GTPases in living cells. Methods Enzymol 406: 296-315.
61. Nour M, Fliesler SJ, Naash MI, (2008) Genetic supplementation of RDS alleviates a loss-of-function phenotype in C214S model of retinitis pigmentosa. Adv Exp Med Biol 613: 129-138.
62. Nour M, Ding XQ, Stricker H, Fliesler SJ, Naash MI, (2004) Modulating expression of peripherin/rds in transgenic mice: critical levels and the effect of overexpression. Invest Ophthalmol Vis Sci 45: 2514-2521.
63. Tam LC, Kiang AS, Kennan A, Kenna PF, Chadderton N, et al. (2008) Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). Hum Mol Genet 17: 2084-2100.
64. Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, et al. (2006) Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci 47: 3052-3064.
65. Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, et al. (1992) A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat Genet 1: 209-213.
66. Chapple JP, Grayson C, Hardcastle AJ, Saliba RS, van der Spuy J, et al. (2001) Unfolding retinal dystrophies: a role for molecular chaperones? Trends Mol Med 7: 414-421.
67. Frederick JM, Krasnoperova NV, Hoffmann K, Church-Kopish J, Ruther K, et al. (2001) Mutant rhodopsin transgene expression on a null background. Invest Ophthalmol Vis Sci 42: 826-833.
68. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, et al. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science 318: 944-949.
69. Illing ME, Rajan RS, Bence NF, Kopito RR, (2002) A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J Bio Chem 277: 34150-34160.
70. Saliba RS, Munro PM, Luthert PJ, Cheetham ME, (2002) The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci 115: 2907-2918.
71. Mao H, James T, Schwein A, Shabashvili AE, Hauswirth WW, et al. (2011) AAV Delivery of Wild-Type Rhodopsin Preserves Retinal Function in a Mouse Model of Autosomal Dominant Retinitis Pigmentosa. Hum Gene Ther 567-575.
72. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, et al. (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118: 69-77.
73. Lee EC, Yu D, Martinez DV, Tessarollo L, Swing DA, et al. (2001) A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73: 56-65.
74. Liu P, Jenkins NA, Copeland NG, (2003) A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 13: 476-484.
75. Ramirez-Solis P, Liu P, Bradley A, (1995) Chromosome engineering in mice. Nature 378: 720-724.
76. Michael F. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108: 107-114.